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Abstract
Runx family transcription factors have risen to prominence over the last few years because of the increasing evidence implicating them as key
regulators of the choice between cell proliferation and differentiation during development and carcinogenesis. Runx factors have been found to be
involved in diverse developmental processes, ranging from hematopoiesis to neurogenesis, and are increasingly being linked with various human
cancers. In this review, we examine the case for Runx factors as key regulators of cell proliferation in various developmental situations, a role that
predisposes Runx mutations as causative agents in oncogenesis. We discuss the evidence that Runx factors regulate, and are regulated by, core
components of the cell cycle machinery, and focus our attention on the solo Runx gene, rnt-1, in Caenorhabditis elegans, an organism that we feel
has much to offer the Runx field.
© 2007 Elsevier Inc. All rights reserved.Keywords: Runx; Development; Cell cycle; C. elegans; Cell proliferationIntroduction
The Runx genes are defined by a highly conserved 128
amino acid DNA binding/protein–protein interaction domain
called the Runt box after the prototypical Runx gene, runt in
Drosphila. Runx genes encode the α subunit of the poly-
omavirus enhancer-binding protein 2/core binding factor
(PEBP2/CBF) transcription factor which was first isolated
based on its ability to bind and activate viral enhancers
(Kamachi et al., 1990; Wang et al., 1993). The β subunit
consists of the non-Runx protein CBFβ. The role of CBFβ is
thought to be two-fold: to increase the affinity of the α subunit
for DNA and to stabilize the α subunit by protecting it from
proteasome-mediated degradation (Adya et al., 1998; Huang et
al., 2001).
Runx factors act as activators or repressors of transcription,
depending on the context in which they bind DNA. This context
is determined by both the cell type and the combination of
different transcription factor binding sites within a particular
target gene regulatory region (Canon and Banerjee, 2003; Stein
et al., 2004). The ability of Runx factors to act as scaffold⁎ Corresponding author. Fax: +44 1865275318.
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them to act as integrators of many different inputs from diverse
signalling pathways, making Runx factors highly regulateable
switches for the key developmental processes of cell prolifera-
tion and differentiation. It is the combinatorial code of factors
bound at particular target promoters that determines the
expression profile of that gene. For example, in the cone cells
of the Drosophila eye, Lozenge (Lz) represses deadpan (dpn)
expression by recruitment of Groucho (Gro) to the dpn
promoter (Canon and Banerjee, 2003). However, the Lz-Gro
interaction is weak and is stabilized by the binding of the
homeodomain protein Cut to a site adjacent to the Lz binding
sites in the dpn promoter (Canon and Banerjee, 2003). The
expression of cut is activated by D-Pax2, which is directly
activated by Lz in cone cells (Fu and Noll, 1997). Thus Runx
factors can act as both direct transcriptional activators and
repressors in the same cell.
At present our understanding of the mechanism of action of
Runx proteins is patchy and restricted to specific target genes,
the nature of which usually reflect the research interests of a
particular group, making it difficult to draw conclusions about
the generality of the different mechanisms that have been
reported. The use of model organisms such as Drosophila and
Caenorhabditis elegans allows for more precise functional
characterization within a whole organism system and also
Fig. 1. Male tail defects in rnt-1 mutants. The male tail in C. elegans is a sensory
organ used to transfer sperm into hermaphrodites during mating and is
composed of a cuticular fan embedded with sensory rays containing neurons and
a proctodeum housing a sclerotised spicule and associated structures used for
sperm transfer. Each ray of the male tail (there are 18 in total) consists of a
structural cell (glial cell) and two associated neurons, with the sensory ending
embedded in the cuticular fan. rnt-1 animals have fewer rays than normal
because of failures in progenitor cell proliferation. (A) wild type male tail, rays
on one side are numbered. (B) rnt-1 mutant with fewer rays. Rays are indicated
by arrows. Scale bar, 10 μm.
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gene function and so may be more useful for revealing
physiologically important interactions and modes of regulation.
Conservation of Runx and CBFβ homologues
There are 3 mammalian Runx genes, Runx1 (aka PEBP2αB/
AML1/CBFA2), Runx2 (aka PEBP2αA/AML3/CBFA1) and
Runx3 (aka PEBP2αC/AML2/CBFA3). Orthologues of each of
these are present in other vertebrates such as zebrafish and
pufferfish in a single copy (except Runx2 which has undergone
duplication in zebrafish). Most invertebrates such as C. elegans
and sea urchin have just one Runx gene (rnt-1 and SpRunt
respectively) (Ito, 2004) although there are 4 Runx genes in
Drosophila (runt, lozenge and two other genes CG15455 and
CG1379) (Rennert et al., 2003). Phylogenetic studies have
indicated that arthropods underwent Runx duplication and
diversification after their divergence from the other protostomes
(Rennert et al., 2003). Thus the single C. elegans Runx
homologue, rnt-1 represents the evolutionarily most primitive
known form of the Runx family. It is therefore likely that the
function of C. elegans rnt-1 will be general to all Runx genes
while the multiple diverged Runx genes in mammals, fish and
flies will have acquired additional region- or tissue-specific
functions after duplication (Rennert et al., 2003). In addition,
the presence of just one Runx gene in C. elegans circumvents
the problem of redundancy associated with the study of Runx
genes in mammals, fish or flies and so should be more amenable
to genetic analysis. These significant advantages, coupled with
the ability to study development at cellular resolution due to its
invariant lineage makes C. elegans an ideal organism in which
to study Runx gene function.
Loss of function rnt-1 mutants in C. elegans were first
isolated on the basis of their male tail phenotype (Fig. 1). mab-2
(found to be allelic with rnt-1) animals have fewer sensory rays
than normal because they lack the correct number of ray
precursor cells (Nimmo et al., 2005). Ray precursor cells are
derived from posterior seam cells of the Vand T lineages, which
divide in a stem cell like pattern throughout larval development
resulting in expansion of the number of progenitors prior to
terminal differentiation. rnt-1 phenotypes are caused by failures
in seam cell proliferation (Nimmo et al., 2005). In addition, the
phasmid (a neuronal structure) is not formed in these mutants
due to a loss of asymmetry in the early T lineage (Kagoshima et
al., 2005).
There is just a single copy of the β subunit CBFβ in
vertebrates and invertebrates with the exception of Drosophila
which has two, brother and big brother. The C. elegans
homologue of CBFβ, BRO-1, is only 36% similar to the
mammalian CBFβ protein. However, we and others have
recently found that bro-1 mutants exhibit very similar defects to
rnt-1 mutants, have overlapping domains of expression and
physically interact in vitro, thus indicating that these two
proteins do indeed interact and function as CBF heterodimers in
transcriptional regulation in C. elegans as they do in other
organisms (Kagoshima et al., 2007; Suad et al., 2007; Xia et al.,
2007).Runx genes as master regulatory switches for lineage
specific differentiation
Runx genes are master regulators of certain differentiative
processes in mammals. The loss of function phenotypes of Runx
knockout mice have been characterized and it was found that
Runx1 is required for definitive hematopoiesis and angiogenesis
(Iwatsuki et al., 2005; Okuda et al., 1996, 1998; Takakura et al.,
2000; Wang et al., 1996), Runx2 is essential for bone formation
(Komori et al., 1997; Otto et al., 1997) and Runx3 is required for
neuronogenesis, thymopoiesis and gut development (Inoue et
al., 2002; Levanon et al., 2002; Li et al., 2002).
Runx genes and cancer
An oncogenic role for Runx factors was revealed by
retroviral insertional mutagenesis which showed that Runx2
(and Runx1/3 to a lesser extent) is a frequent target for proviral
494 R. Nimmo, A. Woollard / Developmental Biology 313 (2008) 492–500insertion in murine leukemia virus (MLV) induced T cell
tumours in CD2-MYC transgenic mice (Stewart et al., 2002;
Wotton et al., 2002). In addition, amplification of Runx1 is
associated with some cases of childhood acute lymphoblastic
leukemia (ALL) and it is possible that increased dosage of
Runx1 in cases of trisomy 21 is causally related to Down's
syndrome-related acute megakaryoblastic leukemia (Roumier et
al., 2003), although recent gene expression profiling studies
may cast doubt on this claim (Bourquoin et al., 2006). The
oncogenic potential of Runx1 is not limited to the lymphoid
lineage as it has been recently shown that increased dosage of
Runx1 positively modulates myeloid leukemogenesis in BXH2
mice which develop leukemia due to insertional mutagenesis by
random integration of a retrovirus (Yanagida et al., 2005).
Runx genes can also act as tumour suppressors as disruption
by translocation induced gene fusion events and hemizygous
deletion and hypermethylation of Runx factors are associated
with various types of cancer. Runx1 translocations are common
in acute myeloid leukemia (AML) and have been shown in
many cases to interfere with normal Runx function either in a
dominant negative fashion or by acting as a constitutive
repressor of Runx target genes. The most common Runx1
fusion protein found in 10–20% of AML, is the product of the t
(8;21) translocation which fuses the N terminal Runt domain to
the heterologous protein partner, ETO. This fusion protein has
been found to interfere with normal Runx1 transactivation of
target genes by acting as a constitutive repressor (Lutterbach et
al., 1998; Meyers et al., 1995; Wildonger and Mann, 2005).
CBFβ is also targeted in the myelomonocytic leukemia-
associated inversion inv(16) which fuses CBFβ to the smooth
muscle myosin heavy chain gene (SMMHC) and either acts as a
constitutive repressor of Runx target genes or sequesters Runx
in the cytoplasm (Adya et al., 1998; Lutterbach et al., 1999).
The fact that loss of Runx1 activation of target genes as a result
of these chromosomal aberrations is oncogenic implies that
Runx1 can act as a tumour suppressor. Further evidence that
these translocations cause loss of Runx1 function is provided by
the observation that transgenic mice expressing these fusion
proteins phenocopy the Runx1 knockout mouse (Castilla et al.,
1996; Okuda et al., 1998; Yergeau et al., 1997).
Runx3 is also proposed to act as a tumour suppressor as
Runx3 knockout mice die soon after birth with increased
epithelial proliferation and hyperplasia in the gastric mucosa (Li
et al., 2002). Indeed gastric cancer cells (and many other
epithelial cancer cells) do not significantly express Runx3 due
to hemizygous deletion and hypermethylation of the promoter
region (Li et al., 2002). However, interpretations of the Runx3
mouse KO phenotypes are controversial and gastric epithelial
hyperplasia has not been described in all studies (Levanon et al.,
2003). Nevertheless, it seems that Runx factors can act both as
proto-oncogenes and tumour suppressors, the nature of which is
highly context-dependent.
Runx genes and cell proliferation
It is not clear whether the role of Runx genes in oncogenesis
arises due to defects in cellular differentiation or cell prolifera-tion. However, there is mounting evidence that Runx factors
regulate cell proliferation directly. Consistent with their role as
oncogenes, they act to promote proliferation in many cell types.
For example, overexpression of the Runx1-P2 (AML1b)
isoform in NIH3T3 fibroblasts results in neoplastic transforma-
tion in vitro and tumour formation in nude mice (Kurokawa et
al., 1996) and has been shown to shorten the G1 phase of 32D.3
myeloid progenitor cells (Strom et al., 2000). In addition it was
recently reported that Runx1 is capable of transforming primary
embryonic fibroblasts in the absence of p53 (Wotton et al.,
2004). However, the transforming ability of Runx1 is lost at low
cell density indicating that its potential to promote proliferation
is context-dependent. It appears that Runx1 activation shortens
the G1 phase of the cell cycle in part by activating cyclin D2 and
D3 expression; this regulationmay be direct as Runx1was found
to bind to elements in their promoters (Bernardin-Fried et al.,
2004; Strom et al., 2000).
In the mammalian nervous system, Runx1 is required to
sustain the proliferation of olfactory receptor neuron (ORN)
precursors and in its absence these cells leave the cell cycle and
differentiate prematurely. The fact that the neuronal progenitors
differentiate prematurely in the absence of Runx1 might imply
that it also has a role in preventing differentiation in addition to
or instead of promoting proliferation. However, exogenous
expression of Runx1 in primary cultures of both olfactory
epithelium (OE)-derived neurosphere-forming cells and cortical
neural progenitor cells increased the number of proliferating
cells without blocking their ability to undergo neural differ-
entiation, resulting in the generation of supernumerary neurons
from an expanded pool of progenitors (Theriault et al., 2005).
As differentiation occurs normally when Runx1 is over-
expressed it seems that the premature differentiation of the
ORN precursors in the absence of Runx1 is likely to be an
indirect effect resulting from the failure to proliferate; it would
seem that differentiation is suppressed in actively proliferating
cells. Interestingly, p21WAF1/CIP1 was found to be repressed
significantly in cortical neural progenitor cells expressing
exogenous Runx1 suggesting that it may be regulated directly
by Runx1 in this cell type (Theriault et al., 2005).
Runx factors are also capable of negatively regulating cell
proliferation. Runx2was isolated as an osteoblast differentiation
factor by the discovery that it binds and activates the osteo-
calcin promoter, and subsequently many other osteogenic
differentiation and bone formation genes (Ducy et al., 1997;
Stein et al., 2004). Runx2 is the principal master switch for
osteogenesis as it activates bone phenotypic genes in pluripotent
cells, redirects a committed premuscle cell to the osteoblast
lineage and inhibits the adipogenic phenotype (Gori et al., 1999;
Lee et al., 1999, 2000). However, in addition to promoting bone
maturation, Runx2 also mediates cell cycle exit of proliferating
osteoprogenitors (Pratap et al., 2003). Runx2 is expressed in
proliferating immature osteoblasts but it fails to activate mature
osteoblast differentiation genes in these progenitor cells,
implying that it has a regulatory function prior to its role in
osteoblast maturation. Indeed calvarial osteogenic cells from
Runx2 deficient mice exhibit enhanced proliferation compared
with wild type cells (Pratap et al., 2003) and ectopic expression
Fig. 2. Differential cell cycle regulation of Runx factors in different cell types. In
the case of osteoprogenitor cells (Ost) Runx2 is acting to suppress proliferation.
Cell cycle-mediated regulation of Runx2 thus ensures that during proliferative
phases the activity of Runx2 is downregulated but is upregulated during G1/G0
in readiness to respond to an unknown differentiative trigger when Runx activity
programs differentiation (Galindo et al., 2005). By contrast, Runx2 in
endothelial cells (EC), where it promotes proliferation, is up-regulated during
G2/M phases and down-regulated during G1/S, presumably leading to a
reduction in cell cycle inhibitor activity (Qiao et al., 2006). In hematopoietic
cells (HC), Runx1 levels rise at the G1/S phase transition in order to promote cell
cycle entry, being low in earlier G1 when the cell is deciding whether to exit the
cell cycle (Bernardin-Fried et al., 2004).
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delay in G1 phase (Galindo et al., 2005). Therefore it seems that
Runx2 is required to suppress proliferation of preosteoblasts in
order for osteoblast differentiation to occur. Both pRB and
p27KIP1 have been found to be required for the antiprolifera-
tive effect of Runx2 and the effect is dependent on Runx2
transactivational activity (Thomas et al., 2004).
In addition to its well characterized role in osteogenesis,
Runx2 is also postulated to be required for angiogenesis
based on in vitro data. In contrast to its role in osteoblasts,
however, here it acts to promote proliferation. Runx2 is
expressed and active in proliferating endothelial cells (ECs)
but activity is lost in quiescent ECs in culture. Indeed, Runx2 is
both necessary and sufficient for EC proliferation and over-
expression in ECs drives increased DNA synthesis and
increased levels of phosphorylated pRB (Qiao et al., 2006;
Sun et al., 2001, 2004). Furthermore Runx2 is able to prevent
TGFβ-mediated growth inhibition, by antagonistic effects on
the expression of p21WAF1CIP1 (Sun et al., 2004). The
opposing roles of Runx2 in regulation of cell proliferation in
osteoblasts and endothelial cells, highlights the dualistic nature
of the Runx factors.
Emerging themes in Runx-mediated regulation of cell
proliferation, Part 1: cross-talk between Runx and the cell
cycle
In order that cell proliferation and differentiation are
correctly balanced, the regulation of the timing of these two
processes must be regulated by the activity of specific factors,
such as MyoD in muscle development. These factors act as a
molecular switch, either by turning off cell proliferation and
turning on terminal differentiation, or vice versa, thus ensuring
the separation of these processes. In turn these factors must be
cross-regulated by the processes of cell proliferation and
differentiation to ensure positive and negative feedback loops
that direct the commitment of a cell to its particular fate, as
defined by its proliferative and differentiative status. MyoD is a
prime example of a transcription factor that controls this balance
perfectly by both inhibiting components of the pRB pathway of
cell cycle regulators and activating downstream myogenic
differentiation factors whilst being subject to negative regula-
tion by CDK2 phosphorylation (Kitzmann and Fernandez,
2001). This cross-talk ensures that actively dividing cells do not
differentiate until the mitogenic signal is attenuated.
Likewise, we propose that the regulation of Runx proteins
during the cell cycle allows them to act as important switches
between the processes of proliferation and differentiation. The
contrasting modes of Runx regulation during the cell cycle in
three different cell types are illustrated in Fig. 2. Consistent with
its role in repressing proliferation of immature osteoblasts and
the concurrent commencement of osteoblast maturation by
direct activation of bone-specific genes, Runx2 is maximally
expressed in G1/G0 and falls at G1/S possibly due to Cyclin D-
Cdk4 induced degradation (Galindo et al., 2005; Shen et al.,
2006) (summarized in Fig. 3). In ECs, on the other hand, Runx2
levels are maximal around the G2/M transition, consistent witha role in promoting cell cycle progression in these cells (Qiao et
al., 2006). Recently, Rajgopal et al. (2007) have shown that
Runx2 is phosphorylated by the CDK1/Cyclin B kinase during
mitosis and is subsequently dephosphorylated by PP1/PP2A
upon mitotic exit. This phosphorylation promotes the intrinsic
DNA binding capacity of Runx2 and may thus maintain its
association with mitotic chromosomes. Indeed, two other recent
reports from the Stein lab have shown that Runx2 remains
associated with target gene promoters during mitosis and
regulates a battery of genes upon mitotic exit (Young et al.,
2007a,b). This mitotic retention of Runx2 may prime the cells to
respond to extracellular differentiation promoting cues such as
BMP signaling once the cell exits mitosis, thus causing the cell
to exit the cell cycle and differentiate.
On the other hand, in hematopoetic cells, Runx1 promotes
proliferation by promoting S phase entry, and consequently
displays almost the opposite expression profile to Runx2 in
osteoblasts, rising at G1/S (Bernardin-Fried et al., 2004). As
Runx1 also promotes differentiation of these cells, it is
important that it does not perform this role while the cells are
actively proliferating. Cyclin D may be acting to distinguish
between the proliferative and differentiative effects of Runx1 in
hematopoetic cells as it represses Runx1 dependent transactiva-
tion of myeloid- and lymphoid-specific differentiation genes,
possibly by competing with CBFβ for binding to the Runt
domain (Peterson et al., 2005). This regulation means that the
commencement of differentiation is prevented until such a time
when growth factor signalling is removed and Cyclin D levels
drop. Furthermore, Cdk-6 has recently been found to inhibit the
Runx1-mediated promotion of granulocytic differentiation via
C/EBPα in a kinase- and Cyclin D-independent manner
(Fujimoto et al., 2007). However, Cdk6 has no effect on the
activation of Cdk4 and Cyclin D2 by Runx1 in 32D myeloid
progenitors thus supporting the hypothesis that cell cycle
regulatory proteins may specifically inhibit the activity of Runx
Fig. 3. Runx2 balances cell proliferation and differentiation during osteoblast
development. Runx2 represses the proliferation of immature osteoblasts via
activation of p27KIP1 which leads to inhibition of S phase cyclin complexes and
a subsequent increase in the hypophosphorylated form of pRB (Thomas et al.,
2004). Runx2 stability is disrupted by ubiquitin-mediated proteasomal
degradation induced by cyclin D-cdk4/6 phosphorylation (Shen et al., 2006),
therefore mitogenic signals would be expected to decrease Runx2 activity.
Runx2 is also responsible for determining the commencement of osteoblast
maturation by directly activating various bone-specific genes such as osteocalcin
and genes required for extracellular matrix deposition (Ducy et al., 1997).
Therefore the involvement of the hypophosphorylated, S phase inhibiting form
of pRB in promoting transactivation of Runx2 target genes required for
differentiation may act as a feedforward loop for ensuring that Runx2 activation
in G1/G0 is reinforced, supporting the onset of senescence and concomitant
commencement of osteoblastic differentiation (Thomas et al., 2001, 2004).
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promote cell cycle progression. In osteoblasts Runx2 also
synergises with C/EBPβ to promote osteocalcin expression
during BMP induced differentiation and this is reduced in
response to ectopically increased Cdk6 levels (Lee et al., 2000).
Therefore it seems that the Runx factors may act as switches
responding to both extracellular cues and intrinsic components
of the cell cycle clock to turn proliferation and differentiation on
and off as required.
An important question in developmental biology is how cell
fate is inherited by daughter cells after mitosis and the finding
that Runx2 associates with target gene promoters on metaphase
chromatids has provided an intriguing answer (Young et al.,
2007b). It will be of great interest to determine if this is
regulated during asymmetric division and especially in stem
cells where self-renewal is determined by the maintenance of
mother cell fate in one or both of the daughters.
Another enigma surrounds the mechanism by which cells
can balance the demands of proliferation and differentiation on
cell growth, specifically the regulation of the ribosomal RNA
(rRNA) genes. It seems that the Runx factors may even provide
a solution to this fundamental problem. Runx2 has been found
bound to rDNA promoter regions on both mitotic and interphase
chromosomes where it regulates chromatin histone modifica-
tions in order to repress rRNA transcription by RNA pol I, thusproviding a link between cell fate, proliferation and growth
control (Young et al., 2007a).
Emerging themes in Runx-mediated regulation of cell
proliferation, Part 2: regulation of cyclin-dependent kinase
inhibitors
Runx1 and Runx2 have both been found to regulate the
expression of cyclin-dependent kinase inhibitors (CKIs). This
regulation can be either positive or negative depending on the
cell type; the p21WAF1/CIP1 promoter contains multiple Runx
binding sites and in NIH3T3 fibroblast cells Runx1-P2
represses the p21WAF1/CIP1 promoter nearly 10-fold while
in K562 myeloid cells it transactivates the p21WAF1/CIP1
promoter by approximately 7-fold (Lutterbach et al., 2000).
Exogenous Runx1 also represses p21WAF1/CIP1 expression in
neural progenitor cells in primary culture (Theriault et al.,
2005). Runx2 was also found to repress the p21WAF1/CIP1
promoter in both fibroblasts and osteoblast lineage cells
(Westendorf et al., 2002) and in endothelial cells Runx2
directly inhibits p21WAF1/CIP1 in competition with TGFβ
signalling and thus promotes EC proliferation (Sun et al., 2004).
By contrast, in fibroblast cell lines, ectopic expression of Runx2
induces p27KIP1 expression to mediate growth arrest, although
it is not known whether this activation is direct (Thomas et al.,
2004). Thus, the dualistic role of Runx factors in either
promoting or inhibiting proliferation may be due to their ability
to activate or repress downstream target genes, such as CKIs, in
a context dependent manner.
A possible problem with much of the data discussed above is
that it is generated in cell lines. In mammalian systems it is very
difficult to analyse cell proliferation and the acquisition of cell
fate in vivo, and researchers are often forced to rely on analyses
of cell populations and tissues rather than individual cells,
making interpretation difficult. Model organisms such as
Drosophila and C. elegans, on the other hand, provide powerful
systems for the in vivo analysis of gene function. In C. elegans
in particular, the invariant lineage presents a unique platform for
the study of development at single cell resolution, and the
presence of solo Runx and CBFβ homologues in this organism
provide further opportunities to exploit this highly tractable
system.
Conservation of Runx factor function in C. elegans:
regulation of cell proliferation in a stem cell-like lineage
The single C. elegans Runx homologue, rnt-1 is required for
cell proliferation in the stem cell-like, epidermal seam cell
lineages. During larval development, in both hermaphrodites
and males, the seam cells have stem cell-like properties as they
undergo self-renewal and expansion whilst producing differ-
entiated epidermal cells via asymmetrical divisions (Fig. 4).
Seam stem cells are multipotent as they contribute a number of
cell types during postembryonic development, including
epidermal cells, adult seam cells, neurons and glial cells.
rnt-1mutant animals have fewer seam cell nuclei in adulthood
which indicates a defect in either the differentiation or
Fig. 4. Seam cell lineage in C. elegans. Seam cells are specialized epidermal cells in C. elegans. At hatching, they are arranged as rows of 10 cells running along each
lateral line (denoted H0–H2, V1–V6 and T). All of them, except for the most anterior, are blast cells, contributing many cells during post-embryonic development.
They divide asymmetrically in a self-renewing stem cell pattern just once at the beginning of each larval stage producing another seam cell that will continue to
proliferate and an epidermal cell that differentiates and fuses with the main epidermal syncytium. In addition, at the beginning of the second larval stage and in a male-
specific developmental program in the posterior seam cells in the third larval stage, seam cells also undergo expansion via symmetrical division. In males, these extra
seam cells eventually give rise to ray precursor cells (R1–R9), from which the sensory rays are derived. Dotted lines denote incomplete lineage diagrams.
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revealed that the seam cells variably fail to divide in rnt-1
mutants, resulting in a reduction in seam cell number (Nimmo et
al., 2005). In males, this results in defective tail formation, as
there are fewer sensory rays resulting from the insufficient
expansion of posterior seam cells (V1–6 and T), discussed above
as generating the sensory rays (Fig. 1) (Nimmo et al., 2005).
bro-1 mutants have recently been isolated and also found to
have reduced seam cell proliferation indicating that BRO-1 doesindeed function as a CBFβ orthologue (Kagoshima et al., 2007;
Xia et al., 2007). In addition, Suad et al., showed that BRO-1
interacts successfully with mammalian Runx and modeling
predicted that it should function in a similar way to CBFβ (Suad
et al., 2007). We discovered that in addition to enhancing the
affinity of RNT-1 for DNA, it also appears to increase the
specificity of RNT-1 for the Runx consensus sequence
(Kagoshima et al., 2007). It will be interesting to discover if
this is a general role of CBFβ proteins.
498 R. Nimmo, A. Woollard / Developmental Biology 313 (2008) 492–500RNT-1 and cell cycle regulation
Intriguingly the overexpression of either bro-1 or rnt-1
causes hyperproliferation of the seam stem cells at the third
larval stage as a result of the cells failing to enter quiescence
after dividing and so undergoing an extra round of division
(Nimmo et al., 2005; Kagoshima et al., 2007). In addition, the
seam cells undergo increased self-renewal as some daughter
progeny fail to differentiate but remain as stem cells. Co-
overexpression of both rnt-1 and bro-1 has a striking effect on
the seam cells causing massive hyperplasia due to the
synergistically enhanced self-renewal capacity of these cells
resulting in a tumor-like appearance (Kagoshima et al., 2007).
Thus rnt-1 and bro-1 are both rate-limiting regulators of seam
stem cell proliferation and self-renewal in C. elegans. As
expected RNT-1 activity absolutely requires BRO-1 to be
functional but intriguingly, the ability of BRO-1 to cause seam
cell hyperplasia appears to be at least partially independent of
RNT-1 activity, suggesting that, in C. elegans at least, bro-1/
CBFβ has some Runx-independent functions (Kagoshima et al.,
2007). The mechanism for this independent role of BRO-1 is
not yet known and it will be interesting to discover whether
other CBFβ proteins also have this ability.
We have some evidence that the activity of rnt-1 may be
regulated by the cell cycle as overexpression in quiescent cells
prior to the time of the G1/S transition is unable to promote an
extra round of division, but overexpression in G2/M appears
to successfully program the cell to re-enter S phase at the
subsequent restriction point, as assayed by the presence of an
extra cell division (Nimmo et al., 2005; Nimmo and Woollard,
unpublished data). These pulses of expression are only
capable of promoting one extra round of division suggesting
that the exogenous RNT-1 may be degraded or inactivated by
passage through the cell cycle. Intriguingly, the CIP/KIP
cyclin-dependent kinase inhibitor homologue, CKI-1 is
upregulated in seam cells in rnt-1 mutants in which the
cells are arrested in a quiescent phase compared to wild type
(Nimmo et al., 2005). Furthermore, depletion of CKI-1 by
RNAi suppresses the seam loss of both rnt-1 and bro-1
mutants (Nimmo et al., 2005; Kagoshima et al., 2007). The
role of rnt-1 may therefore be to allow cell division to occur
by repressing cki-1 at defined points in development in
response to an instructive mitogenic signal. These data
indicate that Runx factors have a conserved role in cell
cycle control via regulation of CIP/KIP proteins in proliferat-
ing stem/progenitor cell lineages.
As in other systems, therefore, the RNT-1/BRO-1 transcrip-
tional complex in C. elegans acts as a switch between the
decision to enter/re-enter or exit the cell cycle at G1. Indeed
ectopic exogenous expression of RNT-1 or BRO-1 in the
committed epidermal daughters of the seam cells that normally
differentiate and fuse with the epidermal syncytium causes these
cells to remain as seam cells and divide again. This is similar to
the situation in neural progenitor cells which differentiate in the
absence of Runx1 induced cell proliferation while overexpres-
sion of Runx1 causes the progenitor cells to undergo extra
rounds of division before terminally differentiating (Theriault etal., 2005). In osteoblast progenitors, Runx2 acts in the opposite
way on proliferation by repressing cell cycle progression
allowing subsequent differentiation to occur (Thomas et al.,
2004). It therefore seems that Runx factors have a conserved
role as molecular switches controlling the developmental
balance between proliferation and differentiation either by
activating cell proliferation such as in C. elegans epidermal
cells and in mammalian neural progenitor cells, or by promoting
differentiation and inhibiting cell cycle progression such as in
osteogenic cells.
Summary
Runx factors are therefore central to the mechanism by
which many cell types control the balance between prolifera-
tion and differentiation during development. These processes
are intimately linked in multicellular development and are not
necessarily mutually exclusive, although terminal differentia-
tion is usually characterized by permanent exit from the cell
cycle. The combined properties of Runx factors to cross-talk
with cell cycle regulatory proteins and transcriptionally
regulate many different target genes both positively and
negatively, depending on context, positions them as key
regulators of the switch between differentiation and prolifera-
tion in many different cell types. They can act both as proto-
oncogenes and tumour suppressors in different situations and it
is a tough challenge to rationalize these seemingly contra-
dictory effects, especially in carcinogenesis. It is a great
advantage in C. elegans to be able to analyze the role of the
single Runx factor, rnt-1 in individual cells within the whole
living organism and we believe this simple organism has much
to offer the field.
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